Satellos Bioscience Inc.
MSLE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001421642
No open-market purchases or sales by Satellos Bioscience Inc. insiders were filed in the last 90 days; 26 institutions reported holding it in 13F filings for Q2 2026, worth $59.6M in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Satellos Bioscience Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 31 | 26 | −5 |
| Shares | 7.60M | 7.68M | +87.4K (+1.2%) |
| Value | $42.8M | $59.6M | +$16.8M (+39.2%) |
New holders (2)
Institutions that held Satellos Bioscience Inc. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| AWM Investment Company, Inc. | 180,000 | $1.40M | 0.12% |
| JPMorgan Chase & Co | 315 | $2.48K | 0.00% |
Sold out (7)
Institutions that held Satellos Bioscience Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| HRT Financial LP | 30,461 | $171.0K |
| Jane Street Group, LLC | 19,608 | $110.4K |
| Monashee Investment Management LLC | 12,000 | $67.6K |
| Propel Bio Management, LLC | 10,145 | $57.1K |
| Axq Capital, LP | 10,096 | $56.8K |
| National Bank of Canada | 2,115 | $11.8K |
| MAI Capital Management | 140 | $789 |